Polymyxin: Alternative mechanisms of action and resistance

Michael J. Trimble, Patrik Mlynárčik, Milan Kolář, Robert Hancock

Research output: Contribution to journalArticle

38 Citations (Scopus)

Abstract

Antibiotic resistance among pathogenic bacteria is an ever-increasing issue worldwide. Unfortunately, very little has been achieved in the pharmaceutical industry to combat this problem. This has led researchers and the medical field to revisit past drugs that were deemed too toxic for clinical use. In particular, the cyclic cationic peptides polymyxin B and colistin, which are specific for Gram-negative bacteria, have been used as “last resort” antimicrobials. Before the 1980s, these drugs were known for their renal and neural toxicities; however, new clinical practices and possibly improved manufacturing have made them safer to use. Previously suggested to primarily attack the membranes of Gram-negative bacteria and to not easily select for resistant mutants, recent research exploring resistance and mechanisms of action has provided new perspectives. This review focuses primarily on the proposed alternative mechanisms of action, known resistance mechanisms, and how these support the alternative mechanisms of action.

LanguageEnglish
Article numbera025288
JournalCold Spring Harbor Perspectives in Medicine
Volume6
Issue number10
DOIs
Publication statusPublished - 1 Oct 2016
Externally publishedYes

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Trimble, Michael J. ; Mlynárčik, Patrik ; Kolář, Milan ; Hancock, Robert. / Polymyxin : Alternative mechanisms of action and resistance. In: Cold Spring Harbor Perspectives in Medicine. 2016 ; Vol. 6, No. 10.
@article{fa8e4bb973d2429fb5c8b627477ab80b,
title = "Polymyxin: Alternative mechanisms of action and resistance",
abstract = "Antibiotic resistance among pathogenic bacteria is an ever-increasing issue worldwide. Unfortunately, very little has been achieved in the pharmaceutical industry to combat this problem. This has led researchers and the medical field to revisit past drugs that were deemed too toxic for clinical use. In particular, the cyclic cationic peptides polymyxin B and colistin, which are specific for Gram-negative bacteria, have been used as “last resort” antimicrobials. Before the 1980s, these drugs were known for their renal and neural toxicities; however, new clinical practices and possibly improved manufacturing have made them safer to use. Previously suggested to primarily attack the membranes of Gram-negative bacteria and to not easily select for resistant mutants, recent research exploring resistance and mechanisms of action has provided new perspectives. This review focuses primarily on the proposed alternative mechanisms of action, known resistance mechanisms, and how these support the alternative mechanisms of action.",
author = "Trimble, {Michael J.} and Patrik Mlyn{\'a}rčik and Milan Kol{\'a}ř and Robert Hancock",
year = "2016",
month = "10",
day = "1",
doi = "10.1101/cshperspect.a025288",
language = "English",
volume = "6",
journal = "Cold Spring Harbor perspectives in medicine",
issn = "2157-1422",
number = "10",

}

Polymyxin : Alternative mechanisms of action and resistance. / Trimble, Michael J.; Mlynárčik, Patrik; Kolář, Milan; Hancock, Robert.

In: Cold Spring Harbor Perspectives in Medicine, Vol. 6, No. 10, a025288, 01.10.2016.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Polymyxin

T2 - Cold Spring Harbor perspectives in medicine

AU - Trimble, Michael J.

AU - Mlynárčik, Patrik

AU - Kolář, Milan

AU - Hancock, Robert

PY - 2016/10/1

Y1 - 2016/10/1

N2 - Antibiotic resistance among pathogenic bacteria is an ever-increasing issue worldwide. Unfortunately, very little has been achieved in the pharmaceutical industry to combat this problem. This has led researchers and the medical field to revisit past drugs that were deemed too toxic for clinical use. In particular, the cyclic cationic peptides polymyxin B and colistin, which are specific for Gram-negative bacteria, have been used as “last resort” antimicrobials. Before the 1980s, these drugs were known for their renal and neural toxicities; however, new clinical practices and possibly improved manufacturing have made them safer to use. Previously suggested to primarily attack the membranes of Gram-negative bacteria and to not easily select for resistant mutants, recent research exploring resistance and mechanisms of action has provided new perspectives. This review focuses primarily on the proposed alternative mechanisms of action, known resistance mechanisms, and how these support the alternative mechanisms of action.

AB - Antibiotic resistance among pathogenic bacteria is an ever-increasing issue worldwide. Unfortunately, very little has been achieved in the pharmaceutical industry to combat this problem. This has led researchers and the medical field to revisit past drugs that were deemed too toxic for clinical use. In particular, the cyclic cationic peptides polymyxin B and colistin, which are specific for Gram-negative bacteria, have been used as “last resort” antimicrobials. Before the 1980s, these drugs were known for their renal and neural toxicities; however, new clinical practices and possibly improved manufacturing have made them safer to use. Previously suggested to primarily attack the membranes of Gram-negative bacteria and to not easily select for resistant mutants, recent research exploring resistance and mechanisms of action has provided new perspectives. This review focuses primarily on the proposed alternative mechanisms of action, known resistance mechanisms, and how these support the alternative mechanisms of action.

UR - http://www.scopus.com/inward/record.url?scp=84991406567&partnerID=8YFLogxK

U2 - 10.1101/cshperspect.a025288

DO - 10.1101/cshperspect.a025288

M3 - Article

VL - 6

JO - Cold Spring Harbor perspectives in medicine

JF - Cold Spring Harbor perspectives in medicine

SN - 2157-1422

IS - 10

M1 - a025288

ER -